The objective of the EAHAD Research Grants is to foster pre-clinical and clinical research collaborations in Europe and to support scientific projects aimed at improving the care of patients with inherited and acquired bleeding disorders.
All scientists and healthcare providers working in the field of inherited and acquired bleeding disorders in Europe may apply (list of eligible countries here: http://www.euro.who.int/en/countries).
The grant application cycle runs from July to October of each year and winners are announced at the annual EAHAD Congress in February. For more information, please contact firstname.lastname@example.org.
2019 Research Grants
The 2019 call for applications is now closed and the winners will be announced on the final day of the EAHAD 2019 Congress.
Dr Alessandro Casini | University Hospitals of Geneva, Geneva, Switzerland
“Interactions between fibrinogen variants and blood cells: towards a predictive model in congenital fibrinogen disorders”
Patients suffering from congenital fibrinogen disorders often have an unpredictable clinical course. Developing methods, which allow the prediction of adverse outcomes, is crucial in order to tailor the best management for these patients. The aim of this project is to determine the interplay between fibrinogen, red blood cells and platelets through the study of the whole blood clot from patients with congenital fibrinogen disorders.
Project duration: October 2018-September 2019
Grant amount: € 45.000
Sébastien Lacroix-Desmazes, PhD, Research Director | INSERM, Centre de Recherche des Cordeliers 15, Paris, France
“High throughput generation and characterization of monoclonal anti-FVIII IgG from patients with hemophilia A”
Treatment of patients with hemophilia A by injection of therapeutic FVIII induces blocking anti-factor VIII antibodies in up to one patient out of three.
In this project, we will isolate the cells that produce anti-factor VIII antibodies from the blood of some patients and generate a large array of single recombinant anti-factor VIII antibodies. We will then establish the ID card of each of the anti-factor VIII antibodies. This will lead to the identification of prognostic markers for successful patient treatment, as well as the development of new treatments to prevent the appearance of or eliminate anti-factor VIII antibodies.
Project duration: March 2018-February 2020
Grant amount: €50,000
Johan Boender, MD | Erasmus University Medical Center, Rotterdam, the Netherlands
“Does ADAMTS13 influence the bleeding phenotype in von Willebrand disease?”
Project duration: April 2017-March 2018
Grant amount: €47,950
Mid-term progress report (Nov 2017): The projects is progressing as scheduled and the first results will be presented as a poster at EAHAD 2018.
Roberta Palla, PhD | Fondazione Luigi Villa, Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy
“High throughput analysis of antibody binding profiles in previously untreated patients with severe haemophilia A”
Project duration: April 2017-March 2019
Grant amount: €50,000